Dear colleagues, we would like to inform you about the inclusion of a new indication – attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years, including hyperactivity, attention deficit, and impulsivity – in the instructions for medical use of the medicinal product “Mexidol®,film-coated tablets, 125 mg”.
According to a multicenter, double-blind, randomized, placebo-controlled, three-group clinical trial evaluating the efficacy and safety of Mexidol®in the treatment of ADHD in children (MEGA), Mexidol®significantly improved the condition of these children and reduced ADHD symptoms by 29%. It improved concentration and focus, increased perseverance, reduced hyperactivity, and decreased impulsivity, leading to improved learning and social adaptation. Furthermore, the study demonstrated a high safety profile for Mexidol, comparable to placebo.
